logo
Sign in

PROTAGONIST THERAPEUTICS, INC.

Milpitas, CA · Biotech · Public

Narrative analysis and measurement software for understanding customer behavior patterns

Claim this profile

Follows are private to you and power your alerts

Updated · protagonist.io

Sector
Biotech
Headquarters
Milpitas, CA
Latest Form D
$17.5M, Jul 2015
Total capital
$28.8M
Federal grants
$4.3M
6 awards · 2015–2019
Rank in peer group#206 of 514
Private capital raised
$24.5M
2 Form D · last Jul 2015
135 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
13
27 pending · first 2022
Rank in peer group#6 of 514

Capital timeline

2013201420152016201720182019FEDERAL ↑EQUITY ↓Cumulative $28.8M$224K$219K$1.3M$374K$1.5M$693K1st Form D$7M2nd Form D$17.5M
2013201520172019FEDERAL ↑EQUITY ↓Cumulative $28.8M$1.3M$374K$1.5M$693K1st Form D$7M2nd Form D$17.5M

Latest events

  • Federal grantHealth and Human S · Phase II · Developing the required biomarkers that define ferroportin target engagement and impact on downstream signaling for clinical translation$693K
  • Federal grantHealth and Human S · Phase II · Developing the required biomarkers that define ferroportin target engagement and impact on downstream signaling for clinical translation$1.5M
  • Federal grantHealth and Human S · Phase II · Developing the required biomarkers that define IL-23R target engagement and effect on downstream signaling for late stage drug development and early clinical proof-of-concept$374K
  • Federal grantHealth and Human S · Phase II · Developing the required biomarkers that define IL-23R target engagement and effect on downstream signaling for late stage drug development and early clinical proof-of-concept$1.3M
  • Federal grantHealth and Human S · Phase I · Hepcidin Mimetics for the Treatment of Iron Overload Diseases$219K
  • Federal grantHealth and Human S · Phase I · Orally delivered antagonists of Interleukin-23 receptor for treatment of inflammatory bowel disease$224K
  • Private capital raisedForm D · SEC · 2nd filing$17.5M
  • Private capital raisedForm D · SEC · 1st filing$7M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grants#206 · top 40%
  • Granted patents#6 · top 1%
  • Linked publications#71 · top 14%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Armen ShanafeltDirectorNamed in SEC Form D filings
  • Armen V. Shanafelt, Ph.D.DirectorNamed in SEC Form D filings
  • Asish K. XavierDirectorNamed in SEC Form D filings
  • Asish K. Xavier, Ph.D.DirectorNamed in SEC Form D filings
  • Dinesh Patel, PhDExecutive Officer, DirectorNamed in SEC Form D filings
  • Harold SelickDirectorNamed in SEC Form D filings
Show all 10 people
  • Harold E. Selick, Ph.D.DirectorNamed in SEC Form D filings
  • Michael K. Panaccio, Ph.D.DirectorNamed in SEC Form D filings
  • Nicholas PeaceDirectorNamed in SEC Form D filings
  • Paul F. TruexDirectorNamed in SEC Form D filings

What it has protected

USPTO · 13 granted of 40
Show all 40 patent records

Recent research by its founders

  • Iron Restricted Erythropoiesis Under Hepcidin Mimetic Treatment (PN23114) Improved Disease Parameters in a Mouse Model for Sickle Cell Disease20230 cites
  • Rusfertide Analog-PN23114 As a Hepcidin Mimetic Provides Efficacy Benefits in Conjunction with Phlebotomy in Mouse Model for Hereditary Hemochromatosis20223 cites
  • PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis202136 cites

Related companies, and why

  • Factor Medical, LLCSimilar federal contract value in Biotech · null in contracts
  • DNATRIX INCSimilar federal contract value in Biotech · null in contracts
  • Auvi Labs, Inc.Similar federal contract value in Biotech · null in contracts
  • ADYNXX, INC.Similar federal contract value in Biotech · null in contracts
  • Distributed Bio, Inc.Similar federal contract value in Biotech · null in contracts
  • IQuity Labs, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .